Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
Tablets: Upgrade Your Understanding Experience - 2Vote in favor of your Number one Kind of Gems
- 3Find Your Internal Culinary expert: Cooking Strategies and Recipes
- 4Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- 5The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Signature Scents: A Manual for Outstanding Fragrances
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- Spain's Easter processions draw more tourists amid Iran war
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- An Extended period of Voyaging Carefully: the World with Reason
